biotech

The 2025 Life Science Outlook focuses specifically on Australia's market developments and opportunities. This regional analysis helps investors understand Australia's role in the global life sciences sector and potential investment opportunities.

The Life Science Outlook World Edition covers global developments from biotech to pharmaceutical breakthroughs. This comprehensive analysis helps investors identify international opportunities in the expanding life sciences sector.

FDA approves leucovorin as the first drug treatment for a rare genetic disorder, following previous promotion by the Trump administration as a potential autism therapy. This regulatory approval could establish a precedent for broader neurological applications and represents a significant milestone in rare disease treatment development.